

ForPatients

by Roche

Autoimmune Hepatitis (AIH)

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Trial Status
Terminated

Trial Runs In
8 Countries

Trial Identifier
NCT04790916 2020-003990-23
BP42698

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04790916 2020-003990-23 BP42698
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No
